Dolan Matthew Vincent's Form 4 filing
Dexcom Inc (DXCM) · filed Mar 17, 2022
- Accession no.
- 0001093557-22-000065
- Filed
- Mar 17, 2022
- Trade date
- Mar 15-17, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $928.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dolan Matthew VincentCIK 0001914994 | Officer (SVP Corporate Development) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2022 | Common Stock | SSaleDisposed | −1,016 | $412.41 | −$419,008.56 | 7,804 | Direct | |
| Mar 16, 2022 | Common Stock | SSaleDisposed | −686 | $425.00 | −$291,550 | 7,118 | Direct | |
| Mar 17, 2022 | Common Stock | SSaleDisposed | −484 | $450.00 | −$217,800 | 6,634 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.